Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cantor biotech/biopharma analysts hold analyst/industry conference call » 12:25
04/08/21
04/08
12:25
04/08/21
12:25
REGN

Regeneron

$478.41 /

-2.97 (-0.62%)

, LLY

Eli Lilly

$183.41 /

+1.12 (+0.61%)

, BMY

Bristol-Myers

$62.20 /

+0.15 (+0.24%)

, PFE

Pfizer

$35.96 /

+0.05 (+0.14%)

, JNJ

Johnson & Johnson

$163.36 /

-0.23 (-0.14%)

, ARQT

Arcutis Biotherapeutics

$27.67 /

-0.32 (-1.14%)

, INCY

Incyte

$81.25 /

-0.205 (-0.25%)

, ACRS

Aclaris Therapeutics

$29.96 /

+0.38 (+1.28%)

, PHGE

BiomX

$6.29 /

-0.07 (-1.10%)

, VYNE

VYNE Therapeutics

$6.47 /

+0.03 (+0.47%)

Biopharma Analysts Chen…

Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PHGE BiomX
$6.29 /

-0.07 (-1.10%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
PFE Pfizer
$35.96 /

+0.05 (+0.14%)

04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
INCY Incyte
$81.25 /

-0.205 (-0.25%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
PHGE BiomX
$6.29 /

-0.07 (-1.10%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

  • 03
    Feb
  • 20
    Jan
  • 02
    Oct
  • 27
    May
REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

ACRS Aclaris Therapeutics
$29.96 /

+0.38 (+1.28%)

VYNE VYNE Therapeutics
$6.47 /

+0.03 (+0.47%)

REGN Regeneron
$478.41 /

-2.97 (-0.62%)

PFE Pfizer
$35.96 /

+0.05 (+0.14%)

LLY Eli Lilly
$183.41 /

+1.12 (+0.61%)

JNJ Johnson & Johnson
$163.36 /

-0.23 (-0.14%)

INCY Incyte
$81.25 /

-0.205 (-0.25%)

BMY Bristol-Myers
$62.20 /

+0.15 (+0.24%)

ARQT Arcutis Biotherapeutics
$27.67 /

-0.32 (-1.14%)

Conference/Events
Cantor biotech/biopharma analysts hold analyst/industry conference call » 04:55
04/08/21
04/08
04:55
04/08/21
04:55
REGN

Regeneron

$481.38 /

+2.48 (+0.52%)

, LLY

Eli Lilly

$182.31 /

-0.31 (-0.17%)

, BMY

Bristol-Myers

$62.05 /

+0.07 (+0.11%)

, PFE

Pfizer

$35.90 /

-0.14 (-0.39%)

, JNJ

Johnson & Johnson

$163.63 /

+0.29 (+0.18%)

, ARQT

Arcutis Biotherapeutics

$27.99 /

+0.19 (+0.68%)

, INCY

Incyte

$81.33 /

-1.8 (-2.17%)

, ACRS

Aclaris Therapeutics

$29.59 /

+0.74 (+2.56%)

, PHGE

BiomX

$6.31 /

-0.1 (-1.56%)

, VYNE

VYNE Therapeutics

$6.44 /

-0.29 (-4.31%)

Biopharma Analysts Chen…

Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PHGE BiomX
$6.31 /

-0.1 (-1.56%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
PFE Pfizer
$35.90 /

-0.14 (-0.39%)

04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
INCY Incyte
$81.33 /

-1.8 (-2.17%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
PHGE BiomX
$6.31 /

-0.1 (-1.56%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

  • 03
    Feb
  • 20
    Jan
  • 02
    Oct
  • 27
    May
REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

ACRS Aclaris Therapeutics
$29.59 /

+0.74 (+2.56%)

VYNE VYNE Therapeutics
$6.44 /

-0.29 (-4.31%)

REGN Regeneron
$481.38 /

+2.48 (+0.52%)

PFE Pfizer
$35.90 /

-0.14 (-0.39%)

LLY Eli Lilly
$182.31 /

-0.31 (-0.17%)

JNJ Johnson & Johnson
$163.63 /

+0.29 (+0.18%)

INCY Incyte
$81.33 /

-1.8 (-2.17%)

BMY Bristol-Myers
$62.05 /

+0.07 (+0.11%)

ARQT Arcutis Biotherapeutics
$27.99 /

+0.19 (+0.68%)

Over a week ago
Conference/Events
Cantor biotech/biopharma analysts hold analyst/industry conference call » 16:20
03/29/21
03/29
16:20
03/29/21
16:20
REGN

Regeneron

$480.99 /

+4.56 (+0.96%)

, LLY

Eli Lilly

$186.25 /

+1 (+0.54%)

, BMY

Bristol-Myers

$64.08 /

+0.135 (+0.21%)

, PFE

Pfizer

$36.62 /

+0.37 (+1.02%)

, JNJ

Johnson & Johnson

$166.03 /

+1.07 (+0.65%)

, ARQT

Arcutis Biotherapeutics

$26.63 /

-1.69 (-5.97%)

, INCY

Incyte

$80.92 /

-0.93 (-1.14%)

, ACRS

Aclaris Therapeutics

$22.56 /

-0.23 (-1.01%)

, PHGE

BiomX

$7.08 /

-0.03 (-0.42%)

, VYNE

VYNE Therapeutics

$6.42 /

-0.44 (-6.41%)

Biopharma Analysts Chen…

Biopharma Analysts Chen & Kim and Biotech Analysts Young & Kluska, along with Dr. Paul Yamauchi, Medical Director at Dermatology Institute & Skin Care Center discuss new and emerging treatments in Medical Dermatology (REGN, LLY, BMY, PFE, JNJ, ARQT, INCY, ACRS, PHGE, VYNE) on an Analyst/Industry conference call to be held on April 8 at 1 pm.

ShowHide Related Items >><<
VYNE VYNE Therapeutics
$6.42 /

-0.44 (-6.41%)

REGN Regeneron
$480.99 /

+4.56 (+0.96%)

PHGE BiomX
$7.08 /

-0.03 (-0.42%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

LLY Eli Lilly
$186.25 /

+1 (+0.54%)

JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

INCY Incyte
$80.92 /

-0.93 (-1.14%)

BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

ARQT Arcutis Biotherapeutics
$26.63 /

-1.69 (-5.97%)

ACRS Aclaris Therapeutics
$22.56 /

-0.23 (-1.01%)

REGN Regeneron
$480.99 /

+4.56 (+0.96%)

03/24/21 Canaccord
Regeneron trial shows positive results against COVID-variants, says Canaccord
03/23/21 Piper Sandler
Regeneron lower dose cocktail likely to be added to EUA, says Piper Sandler
03/11/21 Evercore ISI
Kodiak Sciences initiated with an Outperform at Evercore ISI
03/11/21 Needham
Vir Biotechnology price target raised to $80 from $75 at Needham
LLY Eli Lilly
$186.25 /

+1 (+0.54%)

03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
03/15/21 JPMorgan
Eli Lilly Alzheimer's data more mixed than expected, says JPMorgan
BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
02/12/21 Morgan Stanley
Amgen court decision may have readthrough for Gilead, says Morgan Stanley
02/02/21 BTIG
Prothena upgraded to Buy at BTIG on birtamimab 'revival'
01/20/21 William Blair
Exelixis selloff on competitive concerns an 'overreaction,' says William Blair
PFE Pfizer
$36.62 /

+0.37 (+1.02%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

02/10/21 BTIG
Model N upgraded to Buy from Neutral at BTIG
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
02/01/21 Wells Fargo
Moderna price target raised to $145 from $129 at Wells Fargo
02/01/21 BofA
BofA downgrades Moderna to Underperform, sees shares priced for 'best-case'
ARQT Arcutis Biotherapeutics
$26.63 /

-1.69 (-5.97%)

02/02/21 Truist
Arcutis Biotherapeutics price target raised to $48 from $38 at Truist
02/01/21 Cowen
Arcutis Biotherapeutics price target raised to $80 from $55 at Cowen
01/28/21 JonesTrading
Arcutis Biotherapeutics initiated with a Buy at JonesTrading
11/09/20 Goldman Sachs
Arcutis Biotherapeutics upgraded to Buy from Neutral at Goldman Sachs
INCY Incyte
$80.92 /

-0.93 (-1.14%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
ACRS Aclaris Therapeutics
$22.56 /

-0.23 (-1.01%)

03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
02/02/21 Cantor Fitzgerald
Aclaris Therapeutics price target raised to $30 from $15 at Cantor Fitzgerald
01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
PHGE BiomX
$7.08 /

-0.03 (-0.42%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
VYNE VYNE Therapeutics
$6.42 /

-0.44 (-6.41%)

10/05/20 H.C. Wainwright
VYNE Therapeutics price target raised to $3.50 from $3 at H.C. Wainwright
VYNE VYNE Therapeutics
$6.42 /

-0.44 (-6.41%)

REGN Regeneron
$480.99 /

+4.56 (+0.96%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

LLY Eli Lilly
$186.25 /

+1 (+0.54%)

JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

INCY Incyte
$80.92 /

-0.93 (-1.14%)

BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

ARQT Arcutis Biotherapeutics
$26.63 /

-1.69 (-5.97%)

ACRS Aclaris Therapeutics
$22.56 /

-0.23 (-1.01%)

  • 03
    Feb
  • 20
    Jan
  • 02
    Oct
  • 27
    May
REGN Regeneron
$480.99 /

+4.56 (+0.96%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

LLY Eli Lilly
$186.25 /

+1 (+0.54%)

JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

REGN Regeneron
$480.99 /

+4.56 (+0.96%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

LLY Eli Lilly
$186.25 /

+1 (+0.54%)

JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

ARQT Arcutis Biotherapeutics
$26.63 /

-1.69 (-5.97%)

ACRS Aclaris Therapeutics
$22.56 /

-0.23 (-1.01%)

VYNE VYNE Therapeutics
$6.42 /

-0.44 (-6.41%)

REGN Regeneron
$480.99 /

+4.56 (+0.96%)

PFE Pfizer
$36.62 /

+0.37 (+1.02%)

LLY Eli Lilly
$186.25 /

+1 (+0.54%)

JNJ Johnson & Johnson
$166.03 /

+1.07 (+0.65%)

INCY Incyte
$80.92 /

-0.93 (-1.14%)

BMY Bristol-Myers
$64.08 /

+0.135 (+0.21%)

ARQT Arcutis Biotherapeutics
$26.63 /

-1.69 (-5.97%)

Over a month ago
Conference/Events
Chardan to holda virtual summit » 09:26
03/08/21
03/08
09:26
03/08/21
09:26
KLDO

Kaleido Biosciences

$8.66 /

-0.54 (-5.87%)

, FBRX

Forte Biosciences

$26.95 /

+0.73 (+2.78%)

, MCRB

Seres Therapeutics

$19.06 /

+1.05 (+5.83%)

, SYBX

Synlogic

$3.40 /

+0.3 (+9.68%)

, PHGE

BiomX

$7.05 /

-0.55 (-7.24%)

3rd Annual Microbiome…

3rd Annual Microbiome Medicines Virtual Summit will be held on March 8. Webcast Link

ShowHide Related Items >><<
SYBX Synlogic
$3.40 /

+0.3 (+9.68%)

PHGE BiomX
$7.05 /

-0.55 (-7.24%)

MCRB Seres Therapeutics
$19.06 /

+1.05 (+5.83%)

KLDO Kaleido Biosciences
$8.66 /

-0.54 (-5.87%)

FBRX Forte Biosciences
$26.95 /

+0.73 (+2.78%)

KLDO Kaleido Biosciences
$8.66 /

-0.54 (-5.87%)

02/09/21 Piper Sandler
Kaleido Biosciences initiated with an Overweight at Piper Sandler
01/14/21 Chardan
Kaleido Biosciences price target raised to $17.50 from $10 at Chardan
12/23/20 JMP Securities
Kaleido Biosciences initiated with an Outperform at JMP Securities
10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
FBRX Forte Biosciences
$26.95 /

+0.73 (+2.78%)

11/11/20 Chardan
Forte Biosciences price target raised to $115 from $110 at Chardan
09/24/20 Chardan
Forte Biosciences price target raised to $110 from $60 at Chardan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
09/10/20 Chardan
Forte Biosciences price target raised to $60 from $45 at Chardan
MCRB Seres Therapeutics
$19.06 /

+1.05 (+5.83%)

03/05/21 Chardan
Seres Therapeutics upgraded to Buy from Neutral at Chardan
01/12/21 Piper Sandler
Additional Seres '109 analysis strengthens BLA filing, says Piper Sandler
12/23/20 JMP Securities
Seres Therapeutics initiated with a Market Perform at JMP Securities
11/09/20 Oppenheimer
Seres Therapeutics price target raised to $38 from $34 at Oppenheimer
SYBX Synlogic
$3.40 /

+0.3 (+9.68%)

01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
03/30/20 Piper Sandler
Synlogic's SYNB1819 Phase 1 enrollment slowed by COVID-19, says Piper Sandler
PHGE BiomX
$7.05 /

-0.55 (-7.24%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
SYBX Synlogic
$3.40 /

+0.3 (+9.68%)

MCRB Seres Therapeutics
$19.06 /

+1.05 (+5.83%)

KLDO Kaleido Biosciences
$8.66 /

-0.54 (-5.87%)

  • 04
    Feb
  • 29
    Oct
  • 13
    Aug
  • 02
    Jun
FBRX Forte Biosciences
$26.95 /

+0.73 (+2.78%)

KLDO Kaleido Biosciences
$8.66 /

-0.54 (-5.87%)

FBRX Forte Biosciences
$26.95 /

+0.73 (+2.78%)

Hot Stocks
BiomX announces dosing of first subject in Phase 2 Study of BX001 for acne » 07:33
03/02/21
03/02
07:33
03/02/21
07:33
PHGE

BiomX

$7.97 /

+0.7 (+9.63%)

BiomX announced that the…

BiomX announced that the first subject has been dosed in a Phase 2 cosmetic clinical study of BX001 in subjects with mild-to-moderate acne. BX001 is a topical gel comprised of a cocktail of naturally-occurring phage targeting Cutibacterium acnes. C. acnes are bacteria implicated in the pathophysiology of acne vulgaris. The aim of the study is to provide clinically meaningful improvement of the appearance of acne-prone skin. "The initiation of this study with BX001 marks an important inflection point in the Company's growth as this is our first Phase 2 clinical study," said Jonathan Solomon, Chief Executive Officer of BiomX. "We are encouraged by our prior positive Phase 1 results, in which the BX001 phage cocktail demonstrated a statistically significant reduction of C. acnes levels compared to placebo. This Phase 2 trial of BX001 will evaluate a larger number of subjects with acne-prone skin over 8 to 12 weeks, a duration common in Phase 2 acne studies, with the intention of observing a clinically meaningful effect."

ShowHide Related Items >><<
PHGE BiomX
$7.97 /

+0.7 (+9.63%)

PHGE BiomX
$7.97 /

+0.7 (+9.63%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
Conference/Events
BiomX management to meet virtually with Cantor Fitzgerald » 04:55
02/23/21
02/23
04:55
02/23/21
04:55
PHGE

BiomX

$8.37 /

+0.47 (+5.95%)

Virtual Meetings to be…

Virtual Meetings to be held on February 22-23 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
PHGE BiomX
$8.37 /

+0.47 (+5.95%)

PHGE BiomX
$8.37 /

+0.47 (+5.95%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
Conference/Events
BiomX management to meet virtually with Cantor Fitzgerald » 04:55
02/22/21
02/22
04:55
02/22/21
04:55
PHGE

BiomX

$7.90 /

-0.26 (-3.19%)

Virtual Meetings to be…

Virtual Meetings to be held on February 22-23 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
PHGE BiomX
$7.90 /

-0.26 (-3.19%)

PHGE BiomX
$7.90 /

-0.26 (-3.19%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
Conference/Events
BiomX management to meet virtually with Cantor Fitzgerald » 13:52
02/18/21
02/18
13:52
02/18/21
13:52
PHGE

BiomX

$7.50 /

+0.1 (+1.35%)

Virtual Meetings to be…

Virtual Meetings to be held on February 22-23 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
PHGE BiomX
$7.50 /

+0.1 (+1.35%)

PHGE BiomX
$7.50 /

+0.1 (+1.35%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
Conference/Events
Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call » 09:25
02/18/21
02/18
09:25
02/18/21
09:25
PHGE

BiomX

$7.40 /

+0.07 (+0.95%)

, SYBX

Synlogic

$4.97 /

-0.05 (-1.00%)

Biotechnology Analyst…

Biotechnology Analyst Kluska, along with Duncan Peyton, CEO at 4D Pharma, Jonathan Solomon, CEO at BiomX and Aoife Brennan, CEO at Synlogic, provide an overview of therapeutic strategies and existing evidence of effect in the rapidly developing microbiome space on an Analyst/Industry conference call to be held on February 18 at 10 am. Webcast Link

ShowHide Related Items >><<
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

PHGE BiomX
$7.40 /

+0.07 (+0.95%)

PHGE BiomX
$7.40 /

+0.07 (+0.95%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
03/30/20 Piper Sandler
Synlogic's SYNB1819 Phase 1 enrollment slowed by COVID-19, says Piper Sandler
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

Conference/Events
Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call » 04:55
02/18/21
02/18
04:55
02/18/21
04:55
PHGE

BiomX

$7.40 /

+0.07 (+0.95%)

, SYBX

Synlogic

$4.97 /

-0.05 (-1.00%)

Biotechnology Analyst…

Biotechnology Analyst Kluska, along with Duncan Peyton, CEO at 4D Pharma, Jonathan Solomon, CEO at BiomX and Aoife Brennan, CEO at Synlogic, provide an overview of therapeutic strategies and existing evidence of effect in the rapidly developing microbiome space on an Analyst/Industry conference call to be held on February 18 at 10 am. Webcast Link

ShowHide Related Items >><<
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

PHGE BiomX
$7.40 /

+0.07 (+0.95%)

PHGE BiomX
$7.40 /

+0.07 (+0.95%)

02/02/21 H.C. Wainwright
BiomX overcame 'significant hurdle' with Phase 1a data, says H.C. Wainwright
12/07/20 H.C. Wainwright
BiomX initiated with a Buy at H.C. Wainwright
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

01/13/21 Chardan
Chardan doubles Synlogic target to $10, names top 2021 pick
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Piper Sandler
Piper Sandler remains Overweight on Synlogic after AbbVie ends collaboration
03/30/20 Piper Sandler
Synlogic's SYNB1819 Phase 1 enrollment slowed by COVID-19, says Piper Sandler
SYBX Synlogic
$4.97 /

-0.05 (-1.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.